You just read:

OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

News provided by

OncoSec Medical Incorporated

May 08, 2018, 07:30 ET